InsidersTradesSigma
Total declarations
Companies
▲ Purchases (8 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
8
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-49.2%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Muralidhar Bali, Director. Officer active across 2 companies, notably Reneo Pharmaceuticals, Inc.. In total, 8 filings have been logged. Breakdown: 8 buys · 0 sell. Total volume traded: €1.7m. History available since 26 May 2021. The latest transaction was filed on 19 May 2022 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Muralidhar Bali
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations8 total
1,472,126 shares@ US$0.19370.78% mcap100.0% of flowCommon StockSEC:0001209191-22-030549:0
Canonical exit: 17 Aug 2022 (T+90)
111,736 shares@ US$8.5054.3% of flowCommon StockSEC:0001209191-21-046803:0
Canonical exit: 12 Oct 2021 (T+90)
20,710 shares@ US$9.282710.9% of flowCommon StockSEC:0000905718-21-000834:0
Canonical exit: 21 Sept 2021 (T+90)
32,659 shares@ US$9.030516.7% of flowCommon StockSEC:0000905718-21-000816:0
Canonical exit: 19 Sept 2021 (T+90)
16,605 shares@ US$9.49778.8% of flowCommon StockSEC:0000905718-21-000770:0
Canonical exit: 6 Sept 2021 (T+90)
12,100 shares@ US$9.25156.2% of flowCommon StockSEC:0000905718-21-000760:0
Canonical exit: 1 Sept 2021 (T+90)
14 shares@ US$9.500.0% of flowCommon StockSEC:0000905718-21-000744:0
Canonical exit: 26 Aug 2021 (T+90)
5,915 shares@ US$9.38213.1% of flowCommon StockSEC:0000905718-21-000738:0
Canonical exit: 24 Aug 2021 (T+90)
8 of 8 declarations
About Muralidhar Bali
Muralidhar Bali is an executive at Reneo Pharmaceuticals, Inc.
